EUVIMEDEUVIMED entdecken
Open Access

Endometrial Cancer by ERBB2 Amplification (ERBB2amp) Status: Differences in Molecular Subtypes, Ancestry, and Real-World Outcomes

Evelyn Cantillo iD, Vivek Podder, Natalie Danziger iD, Dale Lobo, Douglas I Lin iD, Ryon P Graf iD, Robert L Coleman iD, Bhavana Pothuri iD, Ramez N Eskander iD, Thomas J Herzog iD, Brian M Slomovitz iD

JCO Precision Oncology · 2026-07 · 10 (7)

DOI: 10.1200/po-25-01157 ↗

Kurz gefasst

Fachartikel in der Zeitschrift JCO Precision Oncology, 2026-07. Verfasst von Evelyn Cantillo und 10 weiteren Autor:innen. Beteiligte Einrichtung: Weill Cornell Medicine, New York, NY. Hauptthemen laut MEDLINE: Endometrial Neoplasms, Erb-b2 Receptor Tyrosine Kinases, Gene Amplification. Die Arbeit nennt 41 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE Endometrial cancer (EC) has rising mortality rates and persistent racial disparities, particularly among non-Hispanic Black women who are more likely to present with aggressive histologic subtypes associated with worse survival. ERBB2 amplification ( ERBB2 amp), a biomarker enriched in aggressive EC subtypes, is a therapeutic target. This study investigates ERBB2 amp prevalence, molecular subtype, and histologic associations, as well as prognostic impact across diverse genetic ancestries using a large clinicogenomic database (CGDB). METHODS We analyzed 16,073 patients with EC who underwent tissue comprehensive genomic profiling via Foundation Medicine. Genetic ancestry was inferred using a single nucleotide polymorphism–based classifier. An outcomes cohort of 1,275 patients with advanced or recurrent EC from the Flatiron Health-Foundation Medicine CGDB was used to assess survival outcomes. Patients receiving human epidermal growth factor receptor 2 (HER2)–targeted therapy were excluded from the overall survival (OS) analysis. ERBB2 amp prevalence, histologic and molecular correlations, and associations with OS were examined. RESULTS ERBB2 amp was identified in 8% of EC tumors, with the highest prevalence among patients of African ancestry (12% v 7% European ancestry; P < .001). There was a significant association between ERBB2 amp and serous histology, TP53 mutation presence, low tumor mutational burden, and microsatellite stability. In the outcomes cohort, ERBB2 amp was not independently associated with OS (hazard ratio, 0.88 [95% CI, 0.65 to 1.17]; P = .37). In contrast, TP53mutation and poor performance status were independently associated with decreased OS. Notably, of patients with documented HER2 immunohistochemistry (IHC; n = 305), 22% of nonamplified tumors exhibited HER2 IHC 2+/3+ staining. CONCLUSION ERBB2 amp is more common among patients with African genetic ancestry and frequently co-occurs with TP53 mutations, providing molecular rationale for EC disparities. Self-reported race does not fully capture genetic ancestry; therefore, comprehensive tumor profiling and HER2 IHC testing should be performed to improve selection for targeted therapies and help address disparities in EC outcomes.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Endometrial NeoplasmsErb-b2 Receptor Tyrosine KinasesGene AmplificationAgedFemaleHumansMiddle AgedBiomarkers, TumorBlack or African AmericanPrognosisWhite

Substanzen

Biomarkers, TumorErb-b2 Receptor Tyrosine KinasesERBB2 protein, human

Autor:innen und Institutionen

  • Weill Cornell Medicine, New York, NY.
  • Mount Sinai Medical Center, Department of Gynecology and Obstetrics, Division of Gynecologic Oncology, Miami Beach, FL.
  • Foundation Medicine, Inc, Boston, MA.
  • University of Cincinnati Cancer Center, Cincinnati, OH.
  • US Oncology Research, The Woodlands, TX.
  • New York University Langone Health, New York, NY.

ORCID-Profile: Evelyn Cantillo, Natalie Danziger, Douglas I Lin, Ryon P Graf, Robert L Coleman, Bhavana Pothuri, Ramez N Eskander, Thomas J Herzog, Brian M Slomovitz

Zitieren

APA

Cantillo, E., Podder, V., Danziger, N., Lobo, D., Lin, D. I., Graf, R. P., Coleman, R. L., Pothuri, B., Eskander, R. N., Herzog, T. J., & Slomovitz, B. M. (2026). Endometrial Cancer by ERBB2 Amplification (ERBB2amp) Status: Differences in Molecular Subtypes, Ancestry, and Real-World Outcomes. JCO Precision Oncology, 10(7). https://doi.org/10.1200/po-25-01157

Vancouver

Cantillo E, Podder V, Danziger N, Lobo D, Lin DI, Graf RP, et al. Endometrial Cancer by ERBB2 Amplification (ERBB2amp) Status: Differences in Molecular Subtypes, Ancestry, and Real-World Outcomes. JCO Precision Oncology. 2026;10(7). doi:10.1200/po-25-01157

BibTeX
@article{Cantillo2026,
  author = {Cantillo, Evelyn and Podder, Vivek and Danziger, Natalie and Lobo, Dale and Lin, Douglas I and Graf, Ryon P and Coleman, Robert L and Pothuri, Bhavana and Eskander, Ramez N and Herzog, Thomas J and Slomovitz, Brian M},
  title = {Endometrial Cancer by ERBB2 Amplification (ERBB2amp) Status: Differences in Molecular Subtypes, Ancestry, and Real-World Outcomes},
  journal = {JCO Precision Oncology},
  year = {2026},
  volume = {10},
  number = {7},
  doi = {10.1200/po-25-01157}
}
Kostenlos starten →